会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 94. 发明授权
    • Novel 4H-1,2,4-triazole derivatives
    • 新型4H-1,2,4-三唑衍生物
    • US4727084A
    • 1988-02-23
    • US896858
    • 1986-08-14
    • Jean MeierFrancois Clemence
    • Jean MeierFrancois Clemence
    • A61K31/41A61P25/04C07C243/38C07D249/08C07D317/46C07D405/04
    • C07D249/08C07C243/38C07D317/46Y10S514/886
    • Compounds selected from the group consisting of 4H-1,2,4-triazoles of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may be in different positions of the benzene ring, R.sub.1, R.sub.3 and R.sub.4 are individually selected from the group consisting of hydrogen, --OH, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, halogen, --CH.sub.3, --NO.sub.2, --NH.sub.2 and NH--AlK and ##STR2## R.sub.2 is selected from the group consisting of hydrogen, --OH, alkyl of 1 to 4 carbon atoms, halogen, --CF.sub.3, --NO.sub.2, --NH.sub.2, --NH--AlK and ##STR3## and AlK, AlK.sub.1 and AlK.sub.2 are alkyl of 1 to 4 carbon atoms or R.sub.1 and R.sub.2 together and/or R.sub.3 and R.sub.4 together are methylenedioxy, R is selected from the group consisting of ethyl, --CH.sub.2 --COOH and CH.sub.2 --COOAlK.sub.3 and AlK.sub.3 is alkyl of 1 to 4 carbon atoms and their non-toxic, pharmaceutically acceptable acid addition salts, with the proviso that R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are not all hydrogen having a remarkable analgesic activity and a novel method for their preparation.
    • 选自下列化合物的化合物的化合物其中R 1,R 2,R 3和R 4可以位于苯环,R 1,R 3和R 4的不同位置的式Ia, 由氢,-OH,1至4个碳原子的烷基,1至4个碳原子的烷氧基,卤素,-CH 3,-NO 2,-NH 2和NH-AlK和R 2选自下组: 的氢,-OH,1至4个碳原子的烷基,卤素,-CF 3,-NO 2,-NH 2,-NH-AlK和AlGaN,AlK,AlK1和AlK2是1至4个碳原子的烷基或R1和 R 2一起和/或R 3和R 4一起是亚甲二氧基,R选自乙基,-CH 2 -COOH和CH 2 -COOAlK 3,AlK 3是1至4个碳原子的烷基及其无毒的药学上可接受的酸加成 盐,条件是R1,R2,R3和R4不都是具有显着镇痛活性的氢和它们制备的新方法。
    • 97. 发明授权
    • 1,2,4-Triazin-3(2H) ones
    • 1,2,4-三嗪-3(2H)酮
    • US4495185A
    • 1985-01-22
    • US436801
    • 1982-10-26
    • David BrownRodney B. HargreavesBernard J. McLoughlinStuart D. Mills
    • David BrownRodney B. HargreavesBernard J. McLoughlinStuart D. Mills
    • A61K31/535A61K31/5375A61K31/54A61P9/04A61P9/12C07C45/00C07C45/64C07C49/82C07C67/00C07C239/00C07C243/38C07C281/04C07D253/06C07D273/04C07D285/16C07D295/18C07D295/21A61K31/53
    • C07D253/06C07C243/38C07C45/64C07D273/04C07D285/16C07D295/21
    • Heterocyclic compounds of the formula ##STR1## wherein either X is --CR.sup.1 R.sup.2 and Y is --O--, --S-- or --NR.sup.3 --, wherein R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each is hydrogen or alkyl of up to 4 carbon atoms;or X is --O--, --S-- or --NH-- and Y is --CR.sup.1 R.sup.2 -- wherein R.sup.1 and R.sup.2 have the meanings stated above;wherein either R.sup.4 is hydrogen, fluoro or chloro, or alkyl, alkenyl, halogenoalkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or alkoxy each of up to 6 carbon atoms, and R.sup.5, R.sup.6 and R.sup.7, which may be the same or different, each is hydrogen, fluoro, chloro, bromo or iodo, or alkyl, alkenyl, halogenoalkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl or alkoxy each of up to 6 carbon atoms, provided that R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are not all hydrogen;or R.sup.4 is bromo and R.sup.5, R.sup.6 and R.sup.7 have the meanings stated above, provided that R.sup.5, R.sup.6 and R.sup.7 are not all hydrogen;or R.sup.4 and R.sup.5 together, or R.sup.5 and R.sup.6 together, or R.sup.4 and R.sup.7 together, form the --CH.dbd.CH--CH.dbd.CH-- group and the other two or R.sup.4, R.sup.5, R.sup.6 and R.sup.7 have the meanings stated above; processes for their manufacture and pharmaceutical compositions containing them. The compounds possess cardiotonic and/or antihypertensive activity.
    • 其中X是-CR 1 R 2和Y的杂环化合物是其中R 1,R 2和R 3可以相同或不同,各自为氢或烷基, 最多4个碳原子; 或X是-O - , - S-或-NH-,Y是-CR 1 R 2 - ,其中R 1和R 2具有上述含义; 其中R 4是氢,氟或氯,或至多6个碳原子的烷基,烯基,卤代烷基,氨基烷基,羟基烷基,烷氧基烷基或烷氧基,以及可以相同或不同的R 5,R 6和R 7各自为氢 ,氟,氯,溴或碘,或各自具有至多6个碳原子的烷基,烯基,卤代烷基,氨基烷基,羟基烷基,烷氧基烷基或烷氧基,条件是R4,R5,R6和R7不全部为氢; 或R 4为溴,R 5,R 6和R 7具有上述含义,条件是R 5,R 6和R 7不全为氢; 或R 4和R 5一起,或R 5和R 6一起,或者R 4和R 7一起形成-CH = CH-CH = CH-基,而另外两个或者R 4,R 5,R 6和R 7具有上述含义; 其制造方法和含有它们的药物组合物。 该化合物具有强心剂和/或抗高血压活性。